In a filing, Abbott Laboratories revealed its Director Blount Sally E. unloaded Company’s shares for reported $0.34 million on Apr 30 ’25. In the deal valued at $129.66 per share,2,600 shares were sold. As a result of this transaction, Blount Sally E. now holds 34,058 shares worth roughly $4.54 million.
Then, SALLY E BLOUNT bought 2,600 shares, generating $337,116 in total proceeds.
Before that, Earnhardt Lisa D sold 91,167 shares. Abbott Laboratories shares valued at $12,199,968 were divested by the EVP AND GROUP PRESIDENT at a price of $133.82 per share. As a result of the transaction, Earnhardt Lisa D now holds 71,928 shares, worth roughly $9.6 million.
Oppenheimer initiated its Abbott Laboratories [ABT] rating to an Outperform in a research note published on October 08, 2024; the price target was $130. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in mid September with a ‘”an Overweight”‘ rating. Edward Jones also remained covering ABT and has decreased its forecast on July 30, 2024 with a “Hold” recommendation from previously “Buy” rating. Goldman started covering the stock on May 30, 2024. It rated ABT as “a Buy”.
Price Performance Review of ABT
On Monday, Abbott Laboratories [NYSE:ABT] saw its stock fall -0.13% to $133.40. Over the last five days, the stock has lost -0.13%. Abbott Laboratories shares have risen nearly 17.94% since the year began. Nevertheless, the stocks have risen 29.23% over the past one year. SMA at 50 days reached $131.06, while 200 days put it at $122.60.
Levels Of Support And Resistance For ABT Stock
The Relative Strength Index (RSI) on the 14-day chart is 53.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 48.26%. Stochastics %K at 55.92% indicates the stock is a holding.
